NEWS RELEASE

Moderna Finalizes Strategic Partnership with UKGovernment
12/21/2022
Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment
and licensure
The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure futurepreparedness in light of the COVID-19 pandemic
Moderna is expanding its presence in the UK through investments in R&D activities and capabilities
CAMBRIDGE, MA / ACCESSWIRE / December 21, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the nalization of a strategic
partnership with the UK government to establish a state-of-the-art mRNA research, development, andmanufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK
government, announced in June 2022.
"Our new state-of-the-art facility will bring mRNA manufacturing to UK shores, providing the UK public with accessto pandemic response capabilities through Moderna COVID-19 vaccines and future respiratory virus vaccine
candidates," said Stéphane Bancel, Chief Executive O cer of Moderna. "We look forward to being part of the UK's
world-renowned science and innovation community, contributing to the UK health ecosystem through signi cantinvestments in R&D activities and expanding our clinical trial footprint across the country."
Once operational, the Moderna Innovation and Technology Centre (MITC) is intended to provide access to a1domestically manufactured portfolio of future mRNA vaccines against respiratory viruses, pending regulatory
assessment and licensure. In addition, the facility is intended to provide the UK with direct access to pandemic
response capabilities, which will support the UK in its global e orts as part of its "100 Days Mission" to reduce theimpact of future pandemics. As part of the ten-year partnership, Moderna will also support the UK's mRNA healthand science ecosystem.
"We are excited to continue our collaboration with the UK government and UK Health Security Agency to establish
the UK as a world-leading mRNA center of excellence," said Darius Hughes, Moderna's General Manager for the UK.
"When constructed, our facility will harness mRNA science with the aim of developing and manufacturing vaccinesthat have the potential to address future threats posed by respiratory viruses."
Construction is expected to commence in early 2023, with the facility expected to become operational by 2025,
subject to planning and regulatory approvals.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programsin the eld of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics
across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle
formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production atscale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of
manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approvalof one of the earliest and most e ective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology
and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases,immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a
top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including regarding: Moderna's agreement with the UK government to develop anmRNA manufacturing facility in the UK, expected timing for commencing construction of the facility, and when thefacility is expected to be operational; the types of medicines to be manufactured at the facility; and the Company's
support of the UK's mRNA research, development and industry ecosystem. The forward-looking statements in this2press release are neither promises nor guarantees, and you should not place undue reliance on these forwardlooking statements because they involve known and unknown risks, uncertainties, and other factors, many of which
are beyond Moderna's control and which could cause actual results to di er materially from those expressed orimplied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks
and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for thescal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31,2022, each led with the U.S. Securities and Exchange Commission (SEC), and in subsequent lings made byModerna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law,Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements
contained in this press release in the event of new information, future developments or otherwise. These forwardlooking statements are based on Moderna's current expectations and speak only as of the date hereof.
Moderna Contacts:
International media: Luke Mircea Willats
Director, Corporate Communications
luke.mirceawillats@modernatx.com
UK Media: Emma Gilgunn-Jones
Director, Communications
emma.gilgunn-jones@modernatx.com
Investors:Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/732840/Moderna-Finalizes-Strategic-Partnership-with-UK-Government

3